Novel dual EP300/CBP bromodomain inhibitors show efficacy in models of mCRPC
Oct. 25, 2023
Opna Bio AG recently provided findings from preclinical studies of novel dual E1A binding protein P300 (EP300) and CREB binding protein (CBP) inhibitors under investigation as potential anticancer agents.
